Therefore CD37 represents a valuable therapeutic target for malignancies derived from peripheral mature B-cells, such as B-cell chronic lymphocytic leukemia (CLL), hairy-cell leukemia (HCL) and NHL. Here, CD37 is linked to B-cell chronic lymphocytic leukemia.